News|Articles|September 3, 2026

5 Hepatology Headlines You Missed in August 2026

Hepatology in August 2026: FDA designations for volixibat and lonafarnib, ketogenic diet liver data, and alcohol use in CLD.

Hepatology news this month centered on regulatory developments in cholestatic and viral liver disease, along with new data on diet-driven liver fat reduction and alcohol use disorder treatment in patients with chronic liver disease.

Related to this article

October 16th, 2026

Diabetes Dialogue: Twiist AID Data and the New ADA/EASD Type 2 Algorithm

Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss a major breakthrough with the Twiist insulin pump and the recent ADA/EASD T2D guidelines.

October 16th, 2026

AASLD Expert Opinion Updates Liver Biopsy Guidance

AASLD’s first Expert Practice Opinion adds EUS-guided biopsy and sets no INR or platelet thresholds.

October 16th, 2026

Elafibranor Lowers ALP in PBC Patients Switching From Obeticholic Acid

Real-world data from ACG 2026 show elafibranor lowered ALP in patients with PBC who switched from obeticholic acid and in those new to second-line therapy.

October 14th, 2026

How GLP-1 RAs May Reduce Liver Fat in MASLD, With Takashi Miki, MD, PhD

In mice, liraglutide reduced steatosis through PPARα without needing iNKT cells, pointing to a possible GLP-1 RA plus PPARα combination.

October 13th, 2026

Bile Acid HDCA Reduces Liver Fat via PPARα, With Takashi Miki, MD, PhD

A Cell Reports mouse study found hepatic steatosis fell without weight loss through separate iNKT cell and GLP-1 pathways.

October 13th, 2026

Efruxifermin Shows Durable Antifibrotic Response in MASH Through 96 Weeks

HARMONY and SYMMETRY data show most early responders to efruxifermin 50 mg maintained fibrosis improvement through 96 weeks, with more responding late.